Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (ABVX) Shares Outstanding (Weighted Average): 2022-2025

Historic Shares Outstanding (Weighted Average) for Abivax (ABVX) over the last 1 years, with Jun 2025 value amounting to $63.4 million.

  • Abivax's Shares Outstanding (Weighted Average) rose 0.78% to $63.4 million in Q2 2025 from the same period last year, while for Dec 2024 it was $62.9 million, marking a year-over-year increase of 0.10%. This contributed to the annual value of $62.9 million for FY2024, which is 0.10% up from last year.
  • Abivax's Shares Outstanding (Weighted Average) amounted to $63.4 million in Q2 2025, which was up 0.11% from $63.3 million recorded in Q1 2025.
  • In the past 5 years, Abivax's Shares Outstanding (Weighted Average) ranged from a high of $63.4 million in Q2 2025 and a low of $42.5 million during Q4 2022.
  • For the 3-year period, Abivax's Shares Outstanding (Weighted Average) averaged around $63.1 million, with its median value being $62.9 million (2024).
  • Data for Abivax's Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 47.77% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Abivax's Shares Outstanding (Weighted Average) stood at $42.5 million in 2022, then soared by 47.77% to $62.9 million in 2023, then rose by 0.10% to $62.9 million in 2024, then grew by 0.78% to $63.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $63.4 million for Q2 2025, versus $63.3 million for Q1 2025 and $62.9 million for Q4 2024.